Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus QVAR 80.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus QVAR 80.
ARMONAIR RESPICLICK vs QVAR 80
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Beclomethasone dipropionate is a corticosteroid that exhibits anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines, chemokines, and arachidonic acid metabolites. It also reduces edema and mucus production in the airways.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
80 mcg orally via oral inhalation twice daily (maximum 320 mcg twice daily)
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal elimination half-life is approximately 2.9 hours after inhalation. This short half-life supports twice-daily dosing but does not fully reflect pulmonary residence time.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Primarily hepatic metabolism, with metabolites excreted in feces (60-70%) and urine (30-40%). Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid